Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
Macrogenics Inc (MGNX) is a clinical-stage biopharmaceutical leader developing antibody-based therapies for cancer and autoimmune diseases. This page aggregates official press releases and verified news about pipeline developments, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on clinical trial progress, FDA designations, and collaborative research initiatives. Our curated feed includes updates on novel antibody candidates, licensing agreements, and financial disclosures—all critical for evaluating the company’s scientific and market trajectory.
Key content areas include monoclonal antibody advancements, oncology trial results, partnership announcements with pharmaceutical leaders, and quarterly earnings reports. Bookmark this page to monitor MGNX’s progress in advancing precision medicine through its proprietary antibody engineering platforms.
MacroGenics (NASDAQ: MGNX) has reported its 2024 financial results and corporate updates. The company completed enrollment in the 150-patient LORIKEET Phase 2 study of lorigerlimab for mCRPC and plans to initiate the LINNET Phase 2 study in ovarian cancer. MacroGenics is advancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028, and MGC030.
Financial highlights include:
- Cash position of $201.7 million as of December 31, 2024
- Total revenue of $150.0 million for 2024, up from $58.7 million in 2023
- Net loss of $67.0 million for 2024
- Cash runway extended into second half of 2026
The company has discontinued internal development of vobra duo and is exploring potential partnering opportunities. Notable developments include the sale of MARGENZA rights to TerSera for $40.0 million upfront, and Incyte's filing of an sBLA for retifanlimab in SCAC with anticipated approval in H2 2025.
MacroGenics (MGNX) has scheduled its fourth quarter and full year 2024 financial results conference call for March 20, 2025, after market close. The biopharmaceutical company, which specializes in developing monoclonal antibody-based cancer therapeutics, will discuss financial performance and recent corporate developments during the call at 4:30 PM ET.
Participants can register in advance for the telephone conference, and a webcast will be available in the Investor Relations section of MacroGenics' website. The webcast recording will be archived for 30 days following the call.
MacroGenics (Nasdaq: MGNX), a biopharmaceutical company specializing in cancer treatment through monoclonal antibody-based therapeutics, has announced its participation in three major investor conferences in March 2025:
- TD Cowen 45th Annual Healthcare Conference in Boston - CEO Scott Koenig will lead a fireside chat on March 5 at 10:30am ET
- Leerink Partners 2025 Global Healthcare Conference in Miami - Fireside chat scheduled for March 11 at 11:20am ET
- Barclays 27th Global Healthcare Conference in Miami - Presentation set for March 12 at 2:00pm ET
The company will conduct one-on-one meetings at all events. Webcasts will be available on MacroGenics' website under the Investor Relations section, with 30-day replay access.
MacroGenics (Nasdaq: MGNX) has announced its participation in the 7th Annual Evercore HealthCONx conference in Coral Gables, FL. The company's President and CEO, Scott Koenig, M.D., Ph.D., will engage in a fireside chat on December 4, 2024, at 7:30am ET, alongside one-on-one meetings.
The presentation will be available via webcast in the Investor Relations section of MacroGenics' website, with an archived replay accessible for 30 days. MacroGenics specializes in developing and commercializing innovative monoclonal antibody-based therapeutics for cancer treatment.
MacroGenics (Nasdaq: MGNX) has announced its participation in two major investor conferences in November 2024. At the Guggenheim Securities Healthcare Innovation Conference in Boston, COO Eric Risser will lead a fireside chat on November 12 at 4:00pm ET. At the Stifel 2024 Healthcare Conference in New York, President & CEO Scott Koenig will conduct a fireside chat on November 18 at 1:15pm ET. Both events will include one-on-one meetings with management. The presentations will be webcast and available for 30 days on MacroGenics' investor relations website.
MacroGenics (NASDAQ: MGNX) reported Q3 2024 financial results with total revenue of $110.7 million, up from $10.4 million in Q3 2023, primarily due to $100 million in milestones from Incyte. The company posted net income of $56.3 million compared to $17.6 million in Q3 2023. Cash position stood at $200.4 million as of September 30, 2024.
Key developments include the pending MARGENZA transaction with TerSera for $40 million upfront plus potential milestone payments up to $35 million, and the submission of an IND application for MGC028, their ADAM9-directed ADC. The company expects its cash runway to extend into 2026.
MacroGenics (NASDAQ: MGNX) announced that CEO Scott Koenig will step down in early 2025. The Board has engaged Heidrick & Struggles to search for a new CEO and formed a special committee to oversee the transition. Under Koenig's 24-year leadership, MacroGenics developed three FDA-approved therapeutics: MARGENZA®, ZYNYZ® for cancer treatment, and TZIELD® for Type 1 diabetes. The company secured over $1 billion in non-dilutive capital through partnerships since its 2013 IPO and maintains a strong balance sheet with multiple antibody-based therapeutics in development.
MacroGenics (MGNX) has scheduled its Q3 2024 financial results conference call for Tuesday, November 5, 2024, after market close. The company will host a conference call at 4:30 pm ET to discuss financial results and recent corporate progress. Participants can register in advance for telephone access, and a webcast will be available under the Investor Relations section of MacroGenics' website. A replay will be archived for 30 days following the call.
Rigrodsky Law, P.A. has announced an investigation into potential claims against MacroGenics (NASDAQ: MGNX) officers and directors on behalf of stockholders. The investigation concerns shareholders who purchased or acquired MacroGenics shares on or before March 7, 2024. Shareholders are encouraged to learn more about their rights through the law firm's website or by contacting their representative.
MacroGenics (NASDAQ: MGNX) has entered into an agreement with TerSera Therapeutics to sell the global rights to MARGENZA® (margetuximab-cmkb), an FDA-approved treatment for metastatic HER2-positive breast cancer. TerSera will pay $40 million at closing, with potential additional sales milestone payments of up to $35 million. The transaction is expected to close in Q4 2024.
MARGENZA, approved in December 2020, is used in combination with chemotherapy for adult patients who have received two or more prior anti-HER2 regimens. This deal allows MacroGenics to focus on advancing its pipeline of oncology product candidates, while TerSera's established U.S. commercial infrastructure may broaden patient access to MARGENZA.
FAQ
What is the current stock price of Macrogenics (MGNX)?
What is the market cap of Macrogenics (MGNX)?
